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From the Southern Association for Vascular Surgery
Results of a single center vascular screening and
education program
Jon A. Hupp, MD, John D. Martin, MD, and Louise O. Hansen, CRNP, Annapolis, Md
Background: Vascular screening events have become a popular way to increase vascular awareness. Most screenings
programs involve multiple locations on a single date and do not explore the local impact of screening. We evaluated the
economic and community impact of the Dare to C.A.R.E. (DTC) program, a large, single center, continuous vascular
screening and education program in Annapolis, Maryland.
Methods: Between July 2000 and July 2006, DTC was offered free to the public for those over 60 or over 50 with risk
factors of hypertension, diabetes, smoking, or elevated cholesterol. DTC consisted of a 2-hour educational lecture,
completing a risk factor questionnaire, and testing blood pressure, carotid duplex, abdominal aortic aneurysm (AAA)
ultrasound, and pedal pulse/ankle-brachial index (ABI). Mild disease (MD) was defined as 1% to 39% carotid stenosis or
an ABI between .7 and .95; intermediate disease (ID) as carotid stenosis >40%, AAA >3 cm, or an ABI <0.7; and severe
disease (SD) as carotid stenosis >60%, AAA >5 cm, or an ABI <0.5. Results were discussed with the participants and
forwarded to their primary physicians. Questionnaire data and screening results were analyzed and local hospital data was
examined to determine the effects of screening.
Results: A total of 12,055 screenings were performed in DTC, 439 were excluded due to age less than 40 or repeat visits,
leaving 11,616 unique patients for this report. Participation grew from 189 in 2000 to over 6400 in 2005. Age ranged
from 40 to 95 (median 65 years) and females comprised 58.7%. Demographics included past smokers (51.3%), current
smokers (7.3%), diabetes mellitus (10.6%), hypertension (46.7%), hyperlipidemia (49.4%), and prior myocardial
infarction (MI) (11.9%). 47% participants had evidence of at least mild disease (MD)with intermediate disease (ID) found
in 6.9% and severe disease (SD) found in 2.2% of patients screened. Statistical analysis showed a greater prevalence of ID
and SD in patients with risk factors. Diabetes alone doubled the prevalence of disease in all age groups. Over 340 hospital
vascular cases were identified in DTC patients in the first 5 years of the program.
Conclusions: The Dare to C.A.R.E. vascular screening and education program is an effective way to detect early and
significant vascular disease. It has a powerful effect on procedural and testing volumes. (J Vasc Surg 2007;46:182-9.)The US Preventative Services Task Force does not
support screening for asymptomatic carotid or peripheral
arterial disease and only supports screening for aneurysms
in men ages 65 to 75 who have smoked tobacco.1,2 The
task force goes on to recommend against screening, sug-
gesting it may lead to an increased number of unnecessary
surgeries and psychological harms. Despite these recom-
mendations, vascular screening programs both by “for
profit” and volunteer organizations continue to evolve.
Vascular screening programs, in addition to the detec-
tion of asymptomatic vascular disease, increase community
awareness of many areas of vascular disease. It is understood
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182that a significant portion of vascular disease, especially
carotid stenosis and abdominal aortic aneurysms, fre-
quently remains undetected until serious complications
occur. All of vascular disease has both genetic and acquired
components and vascular screening offers a unique oppor-
tunity to reinforce the importance of risk factor reduction
and lifestyle changes. While screening programs offer the
potential of early detection, education, and risk factor
reduction, the effectiveness of such programs has yet to be
proven.
In response to a perceived need for more awareness of
vascular disease in our region and our belief in the value of
screening we established a dedicated screening program.
This program, labeled Dare to C.A.R.E. (Carotid artery
stenosis, Abdominal aortic aneurysms, Renal artery steno-
sis, and Extremity artery stenosis) was established with
specific principals:
(1) Free to all participants;
(2) Include didactic session for patient education;
(3) Results and recommendations forwarded directly toprimary care physician;
l caro
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the time of the study; and
(5) No attempt at patient self-referral to specific provider,
group, or institution.
This report is an early analysis of that program includ-
ing demographics, disease detection rates, procedural vol-
ume impact, and an indirect assessment of the impact on
vascular disease awareness.
MATERIALS AND METHODS
The Dare to C.A.R.E. (DTC) screening program was
started in June 2000. Anyone 60 years of ago or older and
individuals 50 years of age or older with risk factors were
encouraged to participate. Risk factors included smoking
history, diabetes, hypertension, hyperlipidemia, or a cardiac
history. Younger individuals, while not encouraged to par-
ticipate, were never turned away.
The screening initially consisted of a two-evening pro-
gram for around 125 participants. The first night was a
2-hour lecture program covering varied topics including
hypertension, cholesterol, stroke, peripheral arterial dis-
ease, abdominal aortic aneurysms, sudden cardiac death,
diabetes, and nutrition. These lectures were given by vari-
ous volunteers including vascular surgeons, cardiologists,
radiologists, and nephrologists. These physicians were
members of multiple competing practices.
During the second night, participants completed a
demographic and risk factor questionnaire and signed a
consent form permitting screening, release of information
to their primary physician, and the use of screening data for
later analysis. Testing included blood pressure determina-
tion, finger-stick cholesterol determination, screening ca-
rotid ultrasound, abdominal aortic aneurysm (AAA) ultra-
sound, and ankle-brachial index (ABI) determination.
Diagnostic criteria for carotid stenosis were the same as
used in our Intersocietal Commission for the Accreditation
of Vascular Laboratories (ICAVL) certified lab with veloc-
ity criteria summarized in Table I. Positive and difficult
studies were verified by an additional technologist if neces-
sary. Renal artery evaluation, although originally at-
tempted, proved to be too time-consuming for high-
volume screening. Despite the fact that screening took
place at night without any pre-study fasting, adequate
aortic imaging was possible in over 99% of patients. ABIs of
1.5, seen only in 0.3% of patients, were not considered as
Table I. Carotid duplex velocity interpretation criteria
Category PSV lower PSV upper EDV l
Normal 0.1 109.9 0
Mild 1%-39% 110.0 129.9 0
Moderate 40%-59% 130.0 169.9 0
Severe 60%-79% 170.0 249.9 40
Critical 80%-99% 250.0 999.9 100
Occluded 0.0 0.0 0
PSV, Peak systolic velocity; EDV, end diastolic velocity; ICA/CCA, internaperipheral arterial disease (PAD) in this study.Upon completion of testing each participant met with a
vascular physician, nurse practitioner, or physicians assis-
tant to review the results. They were given a printed copy of
the results and recommendations and a copy was mailed to
their primary care physician. Primary care physicians were
called the following day if any of their patients were noted
to have critical findings (carotid stenosis 80%, AAA 5
cm, ABI .3). Demographic information, questionnaire
answers, and testing results were entered into a secure
database (Microsoft Access) for later analysis. Data validity
is checked regularly and analysis performed with available
statistical software (SPSS, SPSS Inc, Chicago, Ill).
Mild disease (MD) was defined as 1% to 39% carotid
stenosis or an ABI between .7 and .95; intermediate disease
(ID) as carotid stenosis 40%, AAA 3 cm, or an ABI
0.7; and severe disease (SD) as carotid stenosis 60%,
AAA 5 cm, or an ABI 0.5.
The program was advertised and branded as Dare to
C.A.R.E. with no effort made to link the program to our
local medical facility or to the physicians participating in the
program. While general information was discussed re-
garding management options for participants with vas-
cular disease, no specific treatment recommendations or
self-referrals were made. Participants were encouraged to
return to their primary care physicians for further instruc-
tions. Patients without PCPs were given information about
PCP practices accepting new patients in our area.
Screening events were initially offered on a quarterly
basis with an entirely volunteer staff. After two-years, a
separate foundation was created. Part-time employees were
hired and the program was expanded to daily testing two to
four days per week based on availability of ultrasound
technologists. Interested participants would call a local
number and schedule their appointments. Marketing ma-
terials were distributed to primary care physicians’ offices
and through ads in local newspapers. Additional evening
didactic sessions were added to accommodate the continu-
ous screening patients.
To determine the impact on our local hospital an audit
was conducted by Anne Arundel Medical Center. They
were given access to the Dare to C.A.R.E. (DTC) database
and cross referenced it to the hospital database through
June 2005. All DTC patients who underwent vascular
procedures after attending DTC were identified. Any DTC
patient having a procedure prior to attending DTC was
EDV upper ICA/CCA lower ICA/CCA upper
39.9 0.0 1.4
39.9 1.5 2.9
39.9 1.5 2.9
99.9 3.0 5.9
999.9 6.0 99.9
0.0 0.0 0.0
tid artery/common carotid artery velocity ratio.ower
.0
.0
.0
.0
.0
.0excluded. Unfortunately, imaging studies (ultrasounds,
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by a business unit independent from the hospital.
RESULTS
A total of 12,055 screenings were performed in DTC
from June 2000 though June 2006, 439 were excluded due
to age less than 40 or repeat visits, leaving 11,616 unique
patients for this report. Participation grew from 189 in
2000 to over 6400 in 2005. Participation dropped in early
2006 due to a lack of available vascular technologists.
Screened patients by year are summarized in Fig 1.
Age ranged from 40 to 95 years (mean and median 65
years) and females comprised 59% of the screened patients
(Fig 2).
While patients from 22 different states and the District
of Columbia have been screened, 94% of patients are from
our local “catchment” area and 97.5% of patients are from
the State of Maryland. Demographics included past smok-
ers (51.3%), current smokers (7.3%), diabetes mellitus
(10.6%), hypertension (46.7%), hyperlipidemia (49.4%),
0
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Fig 1. New patients screened by calendar year.
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Fig 2. Patient age and gender distribution.and prior myocardial infarction (MI) (11.9%).Testing results for carotid disease, AAA, and PAD, by
decade are summarized in Tables II, III, and IV. As ex-
pected, AAA detection in females was very low.
The presence of intermediate disease (ID) and severe
disease (SD) are summarized in Table V.
As expected, statistical analysis showed a greater prev-
alence of ID and SD in patients with risk factors. Diabetes
alone more than doubled the prevalence of disease in all age
groups. Overall, diabetics had a 15.9% incidence of ID and
a 5.3% incidence of SD.
Analysis of our local hospitals procedural volume due to
DTC patients is limited and is based on hospital fiscal years
(July 1 to June 30) and only included data through June
30, 2005. Screening volumes were low through fiscal year
2003. Given these limitations, analysis of hospital proce-
dural volume as a result of disease detected in DTC is
summarized in Table VI. Another indirect measure of the
program’s effect is an increase in procedural volumes of
outpatient vascular interventions by 285% over the past 4
years.
Appointments for DTC are routinely booked over 3
months in advance without any continued public market-
ing indicating the effect of awareness in the community. A
significant source of referrals to the program now comes
from local primary care physicians (PCPs). Some early
skepticism by this group has been replaced with enthusi-
asm. 10,685 (92%) of the screened patients designated a
PCP at the time of their screening. A total of 649 different
PCPs are represented in this study with 170 physicians
having 10 or more patients screened, 31 physicians having
more than 100 patients screened, and one physician had
551 of his patients screened.
DISCUSSION
Age adjusted disease detection rates are similar or lower
than those reported in the literature. The preliminary
American Vascular Association (AVA) 2004 Screening pro-
gram results, which looked at 5000 screened Americans
aged 55 and older, had an overall detection rate of 2.5% for
AAA (3 cm), 7.6% for carotid stenosis (50%), and
10.5% for PAD (ABI .85).3 Similar numbers for DTC
with these age criteria yield only 1.8% for AAA, 4.8% for
carotid stenosis, and 2.8% for PAD.
There are actually very few similar “off the street” type
screening programs for comparison. Most of the reported
programs include, either explicitly, or “by association,”
Table II. Testing results—carotid disease detection
Age group (N) 1% 40% (N) 60% (N)
40-49 (433) 24.5% 1.0% (4) 0.5% (2)
50-59 (2496) 29.3% 1.5% (38) 0.7% (18)
60-69 (4870) 44.1% 3.3% (163) 1.2% (57)
70-79 (3049) 63.1% 7.2% (220) 2.6% (80)
80-89 (788) 75.5% 10.3% (81) 4.2% (33)
All (11636) 47.3% 4.4% (506) 1.7% (192)some bias towards patients with cardiovascular diseases.4
(43)
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similar incidence of AAA in males (3.8% vs DTC 4.2% for
same age and size criteria).5 A recent unpublished, industry
sponsored, AAA screening study, completed in 2005, en-
rolled over 8000 voluntary patients and had nearly identical
demographic, gender, and disease detection rates as DTC
(8056 patients screened, 56% female, mean age 66, male
AAA detection rate 3.9%).
If the most important, function of screening is disease
detection then, given our data, it is straightforward to
establish age and gender criteria for screening. For exam-
ple, patients with no risk factors, under age 60, had only a
1.0% chance of having ID and a 0.3% chance of having SD.
Other than reassurance, there is little to be gained by
screening these individuals. Using the data from Tables V
and VI, one can establish what level of disease detection is
“adequate” to justify such a screening program. It is not for
us to say what is “adequate.” Part of DTC’s mission was to
“learn” about screening, therefore, our inclusion criteria
are rather lax. Some programs, with limited resources, may
wish to set the age/gender/risk factor levels higher such
that they have a higher disease detection rate. Referring to
Table V, it is interesting that to obtain an approximate 10%
detection rate of at least ID, one could screen everybody 60
and older or look at men 50 and older and women 70 and
older. Additional risk factor analysis will further define who
benefits from screening.
If education, awareness, and risk reduction are signifi-
cant goals of such programs then the situation changes. As
many as 24% of our low risk factor patients, under age 60,
showed mild (1% to 39%) carotid stenosis. While this
certainly did not require treatment, just showing a 50-year-
old “healthy” individual that their arteries have signs of
Table III. Testing results—AAA
AAA 3 cm
Age group (N) Male Female Both M
40-49 (433) 1.1% (2) 0.4% (1) 0.7% (3) 0.0%
50-59 (2496) 0.9% (8) 0.1% (2) 0.4% (10) 0.4%
60-69 (4870) 2.2% (45) 0.2% (5) 1.0% (50) 0.8%
70-79 (3049) 5.7% (77) 1.3% (22) 3.9% (99) 1.4%
80-89 (788) 6.4% (21) 1.5% (7) 3.6% (28) 0.9%
All (11636) 3.2% (153) 0.5% (37) 1.6% (190) 0.9%
Table IV. Testing results—PAD
Age group (N) ABI 0.95 ABI 0.7 ABI 0.5
40-49 (433) 1.6% (7) 0.9% (4) 0.2% (1)
50-59 (2496) 2.8% (69) 0.4% (9) 0.1% (3)
60-69 (4870) 3.4% (168) 0.9% (44) 0.3% (13)
70-79 (3049) 7.0% (213) 2.9% (87) 1.1% (34)
80-89 (788) 12.1% (95) 4.6% (36) 2.0% (16)
All (11636) 4.8% (552) 1.6% (180) 0.6% (67)
ABI, Ankle-brachial index; PAD, peripheral arterial disease.atherosclerosis can be a powerful influence on medicationcompliance, medical follow-up, and lifestyle changes. Fur-
ther study is needed to see just how much effect such a
screening event has on the individual subsequent behavior.
Vascular screening programs are becoming more com-
mon across the country but little information exists regard-
ing the findings and impact of those programs at the local
level. We believe that existing programs fell short of achiev-
ing our goal of educating the public and primary care
physicians and having a dramatic impact on awareness. We
believe that the five principles, listed in the introduction,
are critical to the long-term successful screening program.
The program was started with very little resources and
used an entirely volunteer staff. Initial success of such
programs is dependant on enthusiasm and dedication of the
health care providers running the program. Equipment and
manpower resources are necessary for a continuous screen-
ing program and this mandates adequate funding, either
provided by an institution or by private fundraising, as was
necessary for our program. One cannot minimize the effort
necessary to establish a self-sustaining program. We have
found the program to be very well received and the interest
and pressure to expand the program was almost immediate.
Demographics. The particular demographics of our
patient base are worth noting. The relatively small percent-
age of active smokers and diabetics contributes to our low
disease detection rates. The very high rate of female partic-
ipants certainly decreases our disease detection, especially
for AAAs. The relative affluence of the region as well as the
natural selection process of people concerned about their
health, the “worried well,” attending screening events is
not unique to our program. This is not a discouraging
finding. Increasing awareness does not require a high inci-
dence of severe disease detection. The mere detection of
even mild disease in almost 50% of our screened population
had a dramatic impact on the frequency by which primary
care physicians sent patients to the program and used more
aggressive risk factor modification. This has been commu-
nicated to us by many of our primary care physicians, and
we plan to address this issue specifically in a future study.
The increased incidence of disease detection in diabetics
suggests that we should be more liberal in our screening of
this population. Preliminary directed screening events at
“higher risk” locations, like assisted living facilities and
geriatric inner-city clinics as well as outreach programs to
underserved retirement geographic areas have shown a
AAA 4 cm AAA 5 cm
Female Both Male Female Both
0.4% (1) 0.2% (1) 0.0% (0) 0.0% (0) 0.0% (0)
0.1% (1) 0.2% (5) 0.0% (0) 0.0% (0) 0.0% (0)
0.1% (2) 0.4% (18) 0.2% (4) 0.0% (0) 0.1% (4)
0.5% (8) 0.9% (27) 0.5% (7) 0.1% (1) 0.3% (8)
0.4% (2) 0.6% (5) 0.3% (1) 0.0% (0) 0.1% (1)
0.2% (14) 0.5% (57) 0.2% (12) 0.0% (1) 0.1% (13)ale
(0)
(4)
(16)
(19)
(3)marked increase in disease detection.
mput
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proached our local hospital for financial and manpower
support to expand the program to outlying areas. This
resulted in increased pressure to quantify the impact of this
program on hospital and practice revenues. This seemed
particularly relevant considering this program was separate
from our hospital, and no specific effort was made to direct
patients to any facility or practice. We initially resisted the
efforts to analyze procedural volume, feeling that revenue
enhancement was not the purpose of the program. It
subsequently became clear this information would be help-
ful for fundraising and program expansion by our center
and other centers nationwide.
While not the purpose of the program, our local med-
ical center has reaped significant financial and “good will”
benefits from being associated with Dare to C.A.R.E. The
local hospital revenues from the vascular procedures and
services related to DTC were significant in the early years of
the program, far exceeding the cost of the program. The
first year start-up cost including equipment, technologists,
administrative staff, postage, printing, and telephone was
approximately $130,000. Once equipment was purchased,
the annual costs fell below $100,000 for the second year of
continuous screening. We expect to screen between 5000
and 6000 patients annually with our continuous screening
program using one full-time vascular technologist. Re-
membering that we used an all volunteer medical staff, once
the program was established the basic cost of screening was
about $25 per patient. Additional costs for equipment
depreciation, service contracts, and liability coverage will
increase this cost.
One also needs to remember that these are rapid
screening exams. For our continuous program we schedule
a new patient every 15 minutes. A single technologist can
screen over 30 patients in an 8-hour workday. Normal
images are not recorded and only a brief half-page result
Table V. Disease detection
Intermediate disease*
Age group Male Female
40 or greater 9.5% 5.0%
50 or greater 9.8% 5.1%
60 or greater 13.5% 7.9%
70 or greater 16.2% 9.8%
80 or greater 19.9% 13.6%
*Intermediate disease ¡carotid 40%, AAA 3 cm or ABI 0.7.
†Severe disease ¡carotid 60%, AAA 5 cm or ABI 0.5.
Table VI. Hospital procedural increases related to Dare to
Hospital fiscal year (does not match calendar year)
Patients screened
Patients with ID or more
Vascular cases on screened patients (excludes, MRA, CTA, VL)
ID, Intermediate disease; MRA, magnetic resonance angiography; CTA, cosheet is completed by the technologist.As mentioned, this vascular screening program is free of
charge. Initially, the program was supported by corporate
and practice donations but once the full-time, continuous
screening was started, a nonprofit foundation was estab-
lished. While donations from screened patients and families
are not actively solicited, last year we received over $42,000
in donations from screening participants and their families
(over 40% of our operating budget).
Screening in general. The US Preventative Services in
1996 and again in 2005 reviewed the literature extensively
regarding vascular screening and arrived at specific recom-
mendations. These recommendations include a single ul-
trasound screening for aneurysms in men ages 65 to 75 who
have ever smoked. These recommendations played a critical
role in the passage of the Screening Abdominal Aortic
Aneurysms Very Efficiently (SAAAVE) Act, which now
provides for one time screening for aneurysms for men with
a smoking history when they have their “Welcome to
Medicare Physical Exam.” This is a start, but certainly
excludes many at-risks individuals from AAA detection.
The efficacy of such screening recommendations has been
shown in other countries.6,7
This task force also went on to recommend against any
other vascular screening including peripheral arterial dis-
ease or carotid disease. They correctly state that there is
inadequate literature that screening saves lives or reduces
morbidity. They feel that screening leads to unnecessary
operations and psychologically harms patients. There are
studies, including the development of the stroke preven-
tion screening (SPS) protocol, that have shown clinical and
economic advantages to screening for preventable causes of
stroke.8 This series of just over 6000 patients showed a cost
advantage of almost $2M despite a cost per screened pa-
tient of over $400. The projected cost-saving if 40 million
Medicare recipients were screened was almost $13 billion.
Carotid screening is currently being re-reviewed by the task
Severe disease†
Both Male Female Both
6.9% 2.8% 1.8% 2.2%
7.0% 2.8% 1.9% 2.3%
0.4% 3.2% 2.3% 2.7%
2.6% 4.9% 3.6% 4.2%
6.3% 7.0% 5.7% 6.2%
.R.E.
00 2001 2002 2003 2004 2005 Total
3 194 169 483 3748 4083 8770
5 13 5 43 253 243 562
0 9 20 15 106 196 346
ed tomography angiography; VL, vascular laboratory.1
1
1C.A
20
9force.
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or carotid disease,9 has shown a very high correlation with
other vascular problems as well as coronary artery disease.10
In one study, PAD had the highest association with critical
carotid stenosis (12.5%) and AAA (5.6%).11 Detection of
PAD likely offers a unique opportunity to find life, brain,
and limb threatening problems at a potentially treatable
stage.
At the heart of the issue are the fundamental questions
of disease prevalence, yield of screening, accuracy, cost,
safety of the diagnostic tests, and finally the effect of detec-
tion on reducing the morbidity and mortality for the
screened patient. While metrics such as cost of quality-
adjusted life year (QALY) and life year gained (LYG)12 are
useful for public health policy, they do little for us to
improve vascular care at the local level.
CONCLUSION
While we might agree that there has yet to be a con-
vincing study that proves early detection of vascular disease
saves lives, the lack of such studies does not necessarily
imply that it does not. Few would argue with the repair of
a 6 cm AAA in an otherwise good risk patient, or carotid
endarterectomy in an asymptomatic 59-year-old with a
critical carotid stenosis. The fact that we are comfortable
offering surgery when we stumble upon a disease, but do
not make an effort to look for the disease in an at-risk
population, appears in conflict. Unlike the noninvasive
detection of lung, breast, and colon cancer, there is no issue
regarding accuracy or safety of duplex ultrasound in the
detection of vascular pathology.13,14 The real issue is cost.
Can we afford broad population screening when critical
disease detection rates are low? The obvious answer is no
and more selective approaches, such as those chosen for
SAAAVE screening, will yield a cost acceptable detection
rate, yet excludes the group most likely to benefit from
screening (relatively young people with premature or early
atherosclerosis).
Dare to C.A.R.E. tries to answers these issues by pro-
viding this service free of charge to a less selective group of
patients. It allows for the more selective and appropriate use
of our practice’s fee-for-service vascular lab and provides a
great opportunity to detect premature and early atheroscle-
rosis at a stage when aggressive risk factor modification may
prevent the need for future interventions. We believe that
the programs key elements are all part of its success and do
not want to underestimate the value of the didactic com-
ponent and the communication with the primary care
physicians. Only further study and time will determine
whether this program truly fulfills its promise of reducing
morbid cardiovascular events. A significant number of our
area’s elderly population has already attended this program
and with participation continuing, future analysis of local
stroke and death rates may further attest to the value of this
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Dr Jerry R. Youkey (Greenville, SC). Over the course of my
15-year journey to the dark side of medicine, I have progressively
become a closet cynic. It has finally become impossible for me to
face the conundrums of our nonsystem of health care without
eagerly anticipating the irreverent monthly editorials of David
Cossman in the “General Surgery News.” It is from that perspec-
tive that I commend Martin, Hupp, and Hanson for their work
presented today. It is refreshing to witness some of our colleagues
initiating a public health program for the benefit of their commu-
nity. My hat is off to you. I also want to thank you for providing me
with your manuscript for review.
I have three general areas of comment, concern, and question
related to your presentation and to your manuscript. These involve
the presentation of your data, your financial analysis, and your lack
of recommendations.
In regards to your data presentation, I find it confusing at best.
Your apparently arbitrary designation of subcritical vascular labo-
ratory results into significant and critical categories in Tables IV
and V is confounding. Significant for what? Critical to whom?
Further, it is completely at odds with the fact that you chose more
traditional values for following day notification of primary care
physicians of truly critical results. I encourage you to change your
end points to laboratory results showing truly critical disease, that
is, carotid stenosis exceeding 80%, aneurysm exceeding 5 cm, and
ABI of less than 0.3, and laboratory results consistent with systemic
noncritical atherosclerosis warranting patient awareness, educa-
tion, and risk reduction.
If you do this, I suspect that statistical analysis of your data will
not support screening of the vast majority of these patients for
critical disease. It is also likely to show that a single limited study for
screening will identify the majority of patients with systemic non-
critical atherosclerosis. Since your data presentation does not allow
identification of the single best test to identify subcritical disease
indicative of systemic atherosclerosis, it is impossible to tell if this is
correct. Have you any insight into an analysis of your data based
upon this hypothesis?
Although I realize that your statements regarding financial
information were largely an after thought, they have given me
limited but specific concerns. First, it is misleading to speak of the
financial benefit of revenues. Groceries and mortgages are paid for
with margin, which brings me to my second concern. I am quite
provide an indication of the presence of subclinical atheroscleroticskeptical of your statement that once the program was established,
the cost of screening was about $25 per patient. Does that figure
include all overhead costs such as lease and upkeep of space,
liability insurances, interpretation fees, equipment depreciation,
office personnel, and so forth? This is an important disclosure for
all of us, as you may well establish with this publication a new
global multitest vascular laboratory reimbursement benchmark for
CMS and private payers across the country.
In closing, I must confess disappoint with your failure to
provide recommendations regarding screening. I was hopeful that
you would have analyzed your data and suggested an algorithm to
identify which patients would benefit from what kind of screening.
I can only surmise that either you plan to carefully follow your
patients to show that long-term compliance with risk reduction
consequent to your efforts will show efficacy of your program
through reduction of morbid cardiovascular events or that you
concluded that no screening could be justified from your data.
Could you please clarify which, if either, of these suppositions is
correct? Again, I commend the authors for their efforts and wish
them success with their foundation-supported cardiovascular
screening program.
Dr Jon A. Hupp: I would like to thank Dr Youkey for
reviewing our manuscript and for his comments. Our definitions
regarding intermediate and severe disease are somewhat arbitrary.
The definition of intermediate disease, having an AAA of at least 3
cm or a carotid stenosis of at least 40% or an ABI of 0.7, would
typically be a patient that deserves follow-up on a yearly basis and
the severe disease level reflects individuals who need intervention
or closer follow-up. We purposely did not make recommendations
regarding who should be screened. One of our goals with Dare to
C.A.R.E. was to be liberal regarding screening criteria such that
we, and others, could look at the data and decide on appropriate
screening criteria based on available resources and desired disease
detection rates (Table V). We certainly want to find silent disease,
but are also were interested in patient education and increased
awareness. We have not attempted to identify any single best test
for systemic atherosclerosis. Future plans do include a patient
follow-up survey to assess patient risk reduction and compliance.
Subgroup analysis of risk factors and disease detection is also
ongoing.INVITED COMMENTARYRuth L. Bush, Temple, Tex
The American Heart Association has estimated that 8 to 12
million Americans are afflicted with peripheral arterial disease
(PAD) and that nearly 75% of PAD patients are asymptomatic.1
We, as vascular specialists, know all to well that the presence of
PAD is associated with an increased risk of cardiovascular morbid-
ity and mortality and that improvements in risk-factor profiles with
behavior modification and pharmacotherapy can decrease the ad-
verse outcomes of stroke, myocardial infarction, and limb loss. The
key issue is the identification of persons at risk before symptomatic
or critical disease becomes present. For that reason, unrecognized
PAD constitutes an enormous public health problem with the
potential for serious, if not fatal, consequences.
Many health organizations, including many professional vas-
cular societies as well as governmental agencies, have recognized
the importance of early screening and thus have joined groups such
as The Peripheral Arterial Disease Coalition to improve both
public and health professional awareness about the disease. It is
well known that a simple ankle-brachial index measurement maydisease, therefore identifying patients who warrant aggressive ed-
ucation and risk-factor management.
As an example, the PAD Awareness, Risk, and Treatment:
New Resources for Survival (PARTNERS) program, a multicenter,
cross-sectional study conducted at 27 sites in 25 cities and 350
primary care practices throughout the United States (US), dem-
onstrated a prevalence of PAD in 29% of patients screened in a
primary care setting, only 11% of whom had classic symptoms of
claudication.2 Furthermore, many persons had been previously
undiagnosed, and as a result of this unawareness, the rate of
intensive treatment for risk factors was low. In addition in this
study, screening tests discovered patients who also, not uncom-
monly, had concomitant cardiac, cerebrovascular, or abdominal
aortic aneurysmal disease.
Martin and colleagues have taken community PAD screening
programs to a new level and have established a new standard to
which all should be upheld. In their unique Dare to C.A.R.E.
program, they have successfully developed a screening program
which include noninvasive testing for vascular disease, glucose and
